Association of inflammation, myocardial fibrosis and cardiac remodelling in patients with mild aortic stenosis as assessed by biomarkers and echocardiography

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 3, 2014, Pages 185-191

  Park, Ji Young ^a   Ryu, Sung Kee ^a   Choi, Jae Woong ^a   Ho, Kim Min ^b   Jun, Jin Hyun ^b   Rha, Seung Woon ^c   Park, Seong Mi ^d   Kim, Hyo Jeong ^a   Choi, Byoung Geol ^c   Noh, Yung Kyun ^e   Kim, Seungwhan ^a  

^a Eulji General Hospital   (South Korea)

^b Eulji University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Aortic stenosis; Echocardiography; Inflammation; Myocardial fibrosis

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AGED; AORTA STENOSIS; AORTA VALVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HEART LEFT ATRIUM; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART RATE; HUMAN; HUMAN TISSUE; INFLAMMATION; M MODE ECHOCARDIOGRAPHY; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AORTIC STENOSIS; ECHOCARDIOGRAPHY; INFLAMMATION; MYOCARDIAL FIBROSIS;

AGED; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 84896386060     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12206     Document Type: Article

References (27)

1. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111: 920-5.
2. Katz R, Wong ND, Kronmal R et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113: 2113-9.
3. Helske S, Oksjoki R, Lindstedt KA et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008; 196: 190-200.
4. Carabello BA. Clinical practice. Aortic stenosis. N. Engl. J. Med. 2002; 346: 677-82.
5. Varo N, Etayo JC, Zalba G et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J. Hypertens. 1999; 17: 107-14.
6. Ng AC, Delgado V, Bertini M et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: A two-dimensional speckle tracking analysis. Eur. Heart J. 2011; 1542: 32-50.
7. Moreo A, Ambrosio G, De Chiara B et al. Influence of myocardial fibrosis on left ventricular diastolic function: Noninvasive assessment by cardiac magnetic resonance and echo. Circ. Cardiovasc. Imaging 2009; 2: 437-43.
8. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc. Res. 1993; 27: 341-8.
9. Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur. J. Heart Fail. 2006; 8: 147-53.
10. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 1993; 21: 1220-5.
11. Kennedy KD, Nishimura RA, Holmes DR Jr, Bailey KR. Natural history of moderate aortic stenosis. J. Am. Coll. Cardiol. 1991; 17: 313-9.
12. Otto CM, Burwash IG, Legget ME et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262-70.
13. Cosmi JE, Kort S, Tunick PA et al. The risk of the development of aortic stenosis in patients with 'benign' aortic valve thickening. Arch. Intern. Med. 2002; 162: 2345-7.
14. Rosenhek R, Klaar U, Schemper M et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur. Heart J. 2004; 25: 199-205.
15. Weidemann F, Herrmann S, Stork S et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009; 120: 577-84.
16. Heymans S, Schroen B, Vermeersch P et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136-44.
17. Leong DP, Madsen PL, Selvanayagam JB. Non-invasive evaluation of myocardial fibrosis. Implications for the clinician. Heart 2010; 96: 2016-24.
18. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-95.
19. Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int. J. Cardiol. 2009; 135: 4-13.
20. Spinale FG, Coker ML, Heung LJ et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-9.
21. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J. Biol. Chem. 1999; 274: 491-4.
22. Theret N, Lehti K, Musso O, Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 1999; 30: 462-8.
23. Kaden JJ, Dempfle CE, Grobholz R et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003; 170: 205-11.
24. Vorovich EE, Chuai S, Li M et al. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am. Heart J. 2008; 155: 992-7.
25. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease. The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 2007; 28: 230-68.
26. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 1986; 57: 450-8.
27. Chen KY, Rha SW, Li YJ et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-14.